top of page

We seek to deliver therapeutic, diagnostic and production benefits in areas as diverse as cancer, immunology, public health and personalised treatment.

Innovation and Technology

Turning Research Into Impact

Our Technology - Invitation for Expression of Interest (EOI)

Name of Technology

Fecal Fungome and Therapeutic Efficacy
of Fecal Microbiota Transplantation


[Invitation for Expression of Interest – Deadline: 19 May 2023]

We are inviting expression of interest (EoI) for commercializing “Fecal Fungome and Therapeutic Efficacy of Fecal Microbiota Transplantation” technology. The innovation is developed by Professor NG Siew Chien, Director of MagIC.

The Technology

The purpose of this invention is to determine if and how donor and recipient fecal fungomes impact FMT efficacy. The invention demonstrates  fecal fungome as one important component influencing FMT efficacy.


The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.

This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.


For inquiries about licensing opportunity, please send email to

Spin-out company

GenieBiome Limited

GenieBiome is established by a team of internationally renowned professors of medicine and clinician-scientists from The Chinese University of Hong Kong. They are among the global top echelon of researchers in the field of gut microbiome with strong academic standing and novel technologies.

90% of us are dominated by microbes in our bodies. GenieBiome pioneers the use of novel microbes as diagnostic markers and potential remedies for different diseases. With an exploding body of global research indicating that the gut microbiome plays a central role in health and disease, GenieBiome has rapidly positioned itself to be a leading force in the development of new diagnostics and therapeutics based on the gut microbiome. It combines cutting-edge and disruptive technologies into a pipeline that enables the prediction of early cancers and debilitating chronic diseases. 

Utilizing our unique in-house dataset and those from publicly available sources, we have identified novel microbes as reliable, non-invasive biomarkers and developed proprietary machine-learning algorithms that can accurately predict disease risk.  

Spin-out company
bottom of page